WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) right this moment introduced that the Company will host an Investor Day on Tuesday, December 6, 2022, on the Lotte New York Palace Hotel, at 8:00am ET.
The program will present a chance for an in-depth take a look at the Company’s hospital-based merchandise, together with CAL02, BARHEMSYS® and BYFAVO®, and Enalare’s ENA-001. Featured audio system embrace Scott Tarriff, President and Chief Executive Officer, senior members of Eagle’s medical and industrial groups, and noteworthy Key Opinion Leaders, who will focus on the scientific rationale and potential unmet medical wants for every pipeline asset and industrial product.
Audience members may have the chance to ask questions following the shows.
Advance registration is required for this occasion. Institutional buyers and analysts are kindly requested to RSVP by way of this hyperlink to attend.
A webcast of this occasion can be accessible through the Company’s web site at www.eagleus.com, underneath the Investors part.
About Eagle Pharmaceuticals, Inc.
Eagle is a totally built-in pharmaceutical firm with analysis and improvement, medical, manufacturing and industrial experience. Eagle is dedicated to growing revolutionary medicines that lead to significant enhancements in sufferers’ lives. Eagle’s commercialized merchandise embrace vasopressin, PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® by way of its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic important care pipeline consists of product candidates with the potential to tackle underserved therapeutic areas throughout a number of illness states. Additional info is offered on Eagle’s web site at www.eagleus.com.
Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
